PPARG and obesity due to melanocortin 4 receptor deficiency: Studies have shown that moderate inhibition of PPARG activity can prevent insulin resistance and obesity induced by high-fat diets, while PPARG antagonists can improve insulin sensitivity and promote the browning of white adipose tissue, potentially offering a safer therapeutic approach [17,18].